CCCC Q1 2024 Earnings — C4 Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CCCCC4 Therapeutics, Inc.

$243M

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M-19.2% YoY

Gross Profit

$3M100.0% margin

Operating Income

-$32M-1060.2% margin

Net Income

-$28M-933.2% margin

EPS (Diluted)

$-0.41

QoQ Revenue Growth

-6.8%

Cash Flow

Operating Cash Flow

-$18M

Free Cash Flow

-$18M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$398M

Total Liabilities

$140M

Stockholders' Equity

$258M

Cash & Equivalents

$90M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$4M	-19.2%
Gross Profit	$3M	-$25M	+112.0%
Operating Income	-$32M	-$36M	+11.1%
Net Income	-$28M	-$35M	+18.5%